Navigation Links
FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Date:1/3/2008

s of VYVANSE were decreased appetite, difficulty falling asleep, stomachache, and irritability.

Aggression, new abnormal thoughts/behaviors, mania, growth suppression, worsening of motion or verbal tics, and Tourette's syndrome have been associated with use of drugs of this type. Tell the doctor if your child has blurred vision while taking VYVANSE.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGFBeta3) and GA-GCB (velaglucerase alfa); manufacturing and
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
2. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
3. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
4. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
5. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
6. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
7. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
8. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
9. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... JOSE, California , January 15, 2014 ... cancer, today announced the appointment of Thomas C Reynolds MD, ... 20 years, development experience gained in the biotechnology industry, most ... "I am delighted to welcome Tom at this transformative time ...
(Date:1/15/2014)... A study has been launched to test whether ... could help to tackle the problem of obesity.  This unique ... surgery based in Stowmarket) and academics at University Campus Suffolk ... technology, which is inspired by equipment used to collect data ...
(Date:1/15/2014)... 15, 2014 The Microcompetition with Foreign DNA ... One of these latent viruses is the Epstein Barr Virus ... Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys ... found that RA patients have high concentrations of EBV DNA ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... at the 2008 Genitourinary Cancers Symposium, ... Inc. announced,today that the Company,s lead cancer ... was well-tolerated in combination with either docetaxel ... with,hormone refractory prostate cancer. Additionally, patients treated ...
... to household cleaners will benefit from new technologies and ... the National Institutes of Health (NIH) and the U.S. ... toxicity testing agreement. The concept behind this agreement is ... journal Science. , Two NIH institutes have formed ...
... 10 a.m.A summary of the National Nanotechnology Initiative (NNI) ... Nanoscale Science, Engineering, and Technology (NSET) Subcommittee of the ... report is a supplement to the Presidents Budget for ... budget request, as well as highlights of planned activities ...
Cached Biology Technology:OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 2OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 3OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 4NIH collaborates with EPA to improve the safety testing of chemicals 2NIH collaborates with EPA to improve the safety testing of chemicals 3National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights 2
(Date:4/17/2014)... Razzari of the nergie Matriaux Tlcommunications Research Centre ... John R. Evans Leaders Fund of the Canada ... state-of-the-art biotech and nanophotonics equipment. To this funding ... de l,Enseignement suprieur, de la Recherche, de la ... laboratories will help us develop new approaches for ...
(Date:4/17/2014)... Our eyes not ... with a continuous stream of information about our own movements. ... a car the world glides by us and leaves ... our brain calculates self-motion from this "optic flow". This way, ... during our own movements. Together with biologists from the University ...
(Date:4/17/2014)... eight years ago, Katia Silvera , a postdoctoral scholar ... on a field trip in a mountainous area in central ... seen before. , Unable to identify it, they contacted German ... out to be an unnamed species. So Carnevali recently named ... is the genus name, comprising about 40 species in the ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... this week in The Lancet Infectious Diseases ... bacterial infection that causes pneumonia, meningitis and sepsis ... a blood disorder prevalent in African children that increases ... study underscores the critical need for use of pneumococcal ...
... Could one of South America,s greatest military figures ... tuberculosis assumed at the time of his death in ... known as "El Libertador" or "The Liberator" ... Historical Clinicopathological Conference (CPC), sponsored by the University of ...
... 2010) Eighty percent of health problems and five million ... water and sanitation according to the World Water Development Report ... for rural villagers, highlights a dire need for reliable access ... aims to solve. The Lemelson-MIT Program today announced ...
Cached Biology News:Vaccines preventing pneumococcal disease protect African children with sickle-cell disease 2Vaccines preventing pneumococcal disease protect African children with sickle-cell disease 3Historic medical conference finds Bolivar may have been poisoned 2Historic medical conference finds Bolivar may have been poisoned 3Historic medical conference finds Bolivar may have been poisoned 4Inventor honored for tech improving access to clean water, healthcare, and business development in India 2Inventor honored for tech improving access to clean water, healthcare, and business development in India 3Inventor honored for tech improving access to clean water, healthcare, and business development in India 4
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... (MUC3) is a glycoprotein. distributed in ... extent in breast, lung and salivary gland ... cross-reaction with MUC1 and MUC2. ... Immunogen: MUC3 tandem repeat peptide ...
... caudal-related homeobox family, is an intestine-specific transcription ... in intestinal epithelial cells. It plays an ... phenotype of differentiated villus enterocytes as well ... Clone CDX2-88 reacts with a conserved epitope ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Biology Products: